A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm-Reference-Cited by-同舟云学术

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm

Published:2017-05-26 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Casolari D. A.,Nguyen T.,Butcher C. M.,Iarossi D. G.,Hahn C. N.^ORCID,Bray S. C.,Neufing P.,Parker W. T.,Feng J.,Maung K. Z. Y.,Wee A.,Vidovic L.,Kok C. H.,Bardy P. G.,Branford S.,Lewis I. D.,Lane S. W.,Scott H. S.,Ross D. M.^ORCID,D’Andrea R. J.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-02655-7.pdf

Reference34 articles.

1. Coombs, C. C., Tallman, M. S. & Levine, R. L. Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol 13, 305–318, doi: 10.1038/nrclinonc.2015.210 (2016).

2. Grand, F. H. et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113, 6182–6192, doi: 10.1182/blood-2008-12-194548 (2009).

3. Skoda, R. C., Duek, A. & Grisouard, J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol 43, 599–608, doi: 10.1016/j.exphem.2015.06.007 (2015).

4. Li, J. et al. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood 123, 3139–3151, doi: 10.1182/blood-2013-06-510222 (2014).

5. Greenall, S. A. et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene 34, 5277–5287, doi: 10.1038/onc.2014.448 (2015).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas;Cell & Bioscience;2023-11-14

2. Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas;2023-07-27

3. Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects;Cancer Research;2022-05-03

4. Genetic Background of Polycythemia Vera;Genes;2022-04-02

5. The active ingredients and mechanisms of Longchai Jiangxue Formula in treating PV, based on UPLC/Q-TOF-MS/MS, systematic pharmacology, and molecular biology validation;Biomedicine & Pharmacotherapy;2021-08